Nyxoah S.A.
NASDAQ•NYXH
CEO: Mr. Robert Taub MBA
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Listing Date: 2021-04-28
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Contact Information
Market Cap
$55.05M
P/E (TTM)
-0.6
40.3
Dividend Yield
--
52W High
$8.59
52W Low
$1.26
52W Range
Rank56Top 81.7%
2.5
F-Score
Modified Piotroski Analysis
Based on 8-year fundamentals
Weak • 2.5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2018-2025
Deep Research
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data